Bristol-Myers Squibb Co


  • FDA clears Eliquis for new use against blood clots Thursday, 21 Aug 2014 | 3:10 PM ET

    WASHINGTON— Bristol-Myers Squibb and Pfizer said Thursday that federal regulators have expanded approval of their blood thinner Eliquis to treat two types of dangerous blood clots. The Food and Drug Administration cleared the drug for patients suffering from or at risk of deep vein thrombosis and pulmonary embolism.

  • Midday Glance: Pharmaceuticals companies Thursday, 21 Aug 2014 | 1:22 PM ET

    Baxter International Inc. rose$. 71 or. 9 percent, to $75.96. Bristol-Myers Squibb Co. fell$. 13 or. 2 percent, to $49.92. Hospira fell$. 12 or. 2 percent, to $54.79.

  • Final Glance: Pharmaceuticals companies Wednesday, 20 Aug 2014 | 6:02 PM ET

    Baxter International Inc. rose$. 12 or. 2 percent, to $75.25. Bristol-Myers Squibb Co. fell$. 26 or. 5 percent, to $50.04. Hospira rose$. 99 or 1.8 percent, to $54.91.

  • Midday Glance: Pharmaceuticals companies Wednesday, 20 Aug 2014 | 1:49 PM ET

    Baxter International Inc. rose$. 11 or. 1 percent, to $75.24. Bristol-Myers Squibb Co. fell$. 18 or. 4 percent, to $50.12. Hospira rose$. 70 or 1.3 percent, to $54.62.

  • Early Glance: Pharmaceuticals companies Wednesday, 20 Aug 2014 | 12:21 PM ET

    Baxter International Inc. fell$. 35 or. 5 percent, to $74.78. Bristol-Myers Squibb Co. fell$. 16 or. 3 percent, to $50.14. Hospira rose$. 45 or. 8 percent, to $54.37.

  • Diversified U.S. manufacturer 3 M Co and medical equipment makers CareFusion Corp and C.R. Bard Inc are among the companies exploring a potential deal for ConvaTec, the people said. CareFusion, with a market capitalization of $9 billion, and C.R. Bard, with $11.2 billion, would both be able to achieve an inversion if they use their own stock to pay for ConvaTec.

  • Why dying kids can't get the drugs they need Tuesday, 5 Aug 2014 | 7:33 AM ET
    Nathalie Traller back in the clinic.

    Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.

  • AstraZeneca steps up push into cancer immunotherapy Thursday, 31 Jul 2014 | 8:51 AM ET

    LONDON, July 31- AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types. AstraZeneca said it would present further data looking at MEDI4736 in lung cancer, as well as early results for head and neck cancer, in September at the annual meeting of the European Society for Medical Oncology.

  • Pfizer beats forecasts as oncology drugs grow Tuesday, 29 Jul 2014 | 10:54 AM ET

    Pfizer reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.

  • Pfizer's need for deal looms with earnings report Monday, 28 Jul 2014 | 7:12 AM ET

    Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.

  • NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

  • July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.

  • NEW YORK, July 24- Major global stock markets edged higher while the euro rose from an eight-month low against the U.S. dollar on Thursday following upbeat euro zone data and stronger-than-expected U.S. earnings.

  • Ford earnings, jobless claims to lift Wall Street Thursday, 24 Jul 2014 | 8:40 AM ET

    U.S. stock index futures rose on Thursday, ahead of one of the heaviest days for U.S. and European second-quarter earnings.

  • Politics fade as earnings take over Friday, 18 Jul 2014 | 6:30 PM ET
    Espirito Santo International is the parent company of several institutions, including Banco Espirito Santo.

    Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.

  • Cramer’s Bristol-Myers theorem: What is it? Monday, 7 Jul 2014 | 6:28 PM ET

    You always hear Cramer shouting about Bristol – Maaah-yerss. Why is that?

  • July 1- Bristol-Myers Squibb Co said it was voluntarily recalling six lots of the injectable version of its blood thinner, Coumadin, in the United States, after particulate matter was found in some unreleased samples.

  • Early movers: NKE, DD, PFE, GM, INTC, BMY & more Friday, 27 Jun 2014 | 7:33 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • NEW YORK, June 25- U.S. stock investors ignored weak economic data and pushed equities higher on Wednesday, as drugmakers' shares rose and a Supreme Court ruling lifted major broadcaster stocks, while German bond yields hit the year's low on safe-haven bids.

  • US STOCKS-Wall St gains with drugmakers, broadcasters Wednesday, 25 Jun 2014 | 5:09 PM ET

    *Monsanto rallies on outlook and stock-repurchase plans. *CBS shares jump after Supreme Court ruling. Shares of CBS jumped 6.2 percent to $62.48 after the U.S. Supreme Court ruled that online TV startup Aereo Inc violates copyright law by using tiny antennas to provide subscribers with broadcast network content via the Internet.